<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33504">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965119</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2013-06-039</org_study_id>
    <nct_id>NCT01965119</nct_id>
  </id_info>
  <brief_title>Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma</brief_title>
  <acronym>JAK2</acronym>
  <official_title>Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is that ruxolitinib may be a possible treatment option for
      relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the efficacy of disease control  including complete response (CR), partial response (PR) and stable disease (SD)</measure>
    <time_frame>From date of enrollment until the date first documented disease progression or unacceptable toxicity, whichever came first, assessed up to 48months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>from the date of informed consent signature to 30days after last drug administration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>CTCAE v4 (Common Terminology Criteria for Adverse Events v4.0) In the present study, toxicities will be recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (CTCAE), version 4.0. The full CTCAE documentation is available on the NCI web site, at the following address: http://ctep.cancer.gov/forms/CTCAEv4.pdf The occurrence of severe adverse event (SAE) should be also reported to the Novartis Safety Office within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overal Survival</measure>
    <time_frame>from the date of first drug administration until the date of death, assessed up to 48months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed or Refractory Hodgkin Lymphoma</condition>
  <condition>Primary Mediastinal Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <other_name>jakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven Hodgkin lymphoma or primary mediastinal large B-cell lymphoma

          -  Patient should belong to any one of following clinical situations A.Patient who are
             not able to get autologous stem cell transplantation after relapsing the salvage
             chemotherapy B. Relapsed after autologous stem cell transplantation C. Refractory to
             salvage chemotherapy or autologous stem cell transplantation

          -  Adequate organ function as defined by the following criteria:

        A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and
        serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤2.5 x local
        laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if
        liver function abnormalities are due to underlying malignancy B. Total serum bilirubin
        ≤1.5 x ULN C. Absolute neutrophil count (ANC) ≥ 1500/µL D. Platelets ≥ 100,000/µL E.
        Hemoglobin ≥ 9.0 g/dL (may be transfused or erythropoietin treated) F. Serum calcium ≤
        12.0 mg/dL G. Serum creatinine ≤ 1.5 x ULN

          -  At least one measurable lesion

          -  ECOG PS 0-2

          -  Informed consent

          -  Age from 19 to 80

        Exclusion Criteria:

          -  Previously received allogeneic stem cell transplantation

          -  History of or known carcinomatous meningitis, or evidence of symptomatic
             leptomeningeal disease or secondary CNS involvement on CT or MRI scan.

          -  Currently uncontrolled active infection

          -  Previous history of recurrent herpes zoster or recurrent tuberculosis

          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2.

          -  Pregnant or lactating females or patients who ar not willing to use an adequate
             method of birth control for the duration of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Seog Kim, PhD</last_name>
    <phone>82-2-3410-6548</phone>
    <email>wonseog.kim@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seok Jin Kim, PhD</last_name>
    <phone>82-2-3410-1766</phone>
    <email>seokjin88.kim@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center of Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyeon Seok Eom</last_name>
      <phone>82-031-920-2402</phone>
      <email>hseom@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Hyeon Seok Eom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam University Hwasoon Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deok-Hwan Yang</last_name>
      <email>drydh1685@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Deok-Hwan Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Kyunggi-do</state>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seong Hyun Jeong</last_name>
      <email>seonghyunmd@naver.com</email>
    </contact>
    <investigator>
      <last_name>Seong Hyun Jeong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byeong-Bae Park</last_name>
      <email>drbbpark@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Byeong-Bae Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dok Hyun Yoon, PH</last_name>
      <phone>82-10-3235-3090</phone>
      <email>dhyoon@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Duk Hyun Yoon, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Park</last_name>
      <email>paark76@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Yong Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Seok Kim</last_name>
      <phone>82-2-2228-1972</phone>
      <email>hemakim@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jin Seok Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korean Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hye Jin Kang</last_name>
      <phone>82-10-2980-9262</phone>
      <email>hyejin@kcch.re.kr</email>
    </contact>
    <investigator>
      <last_name>Hye Jin Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ehwa Womens University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young Chul Moon</last_name>
      <email>yeungchul@ewha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Chul Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Seog Kim</investigator_full_name>
    <investigator_title>M.D., PhD.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
